Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Visiongain Reports | The Global Pain Market, 2008-2023

The Global Pain Market, 2008-2023

The global pain market generated total sales of $34bn in 2007 – but what will the figures be in the next 5 and 10 years? This report tells you.

The pain market has marked strengths and advantages, but is also limited by problems and concerns. The market will be driven by new drugs and reformulations of existing ones – but which drugs will be most successful? The incidence of pain is increasing rapidly, what some experts call a pain epidemic – so the opportunities available to an additional blockbuster drug is significant. The prevention and treatment of pain is already one of the highest priorities for healthcare authorities in the world, yet for mature markets pain drug sales have fallen. However, visiongain believes that this market has strong growth potential, despite the prospect of generic competition for leading branded products.

The pain market contained four blockbuster drugs in 2007. Visiongain predicts that there will be room for more blockbuster drugs in that market segment during the years ahead as new products are launched, replacing older products. There is great potential for treatments with greater safety, efficacy and tolerability. This report - The Global Pain Market, 2008-2023 - provides analysis and forecasts for the overall pain market and its principal subdivisions, as well as for leading products within those categories. This study also highlights promising pipeline developments and important contemporary issues, especially commercial drivers and restraints.

In particular, The Global Pain Market, 2008-2023 analyses global markets for the following groups of pain treatment:

• Non-narcotics

• Narcotics

• Anti-arthritic treatments

• Anti-migraine treatments.

This report delivers:

• Key analysis split by region and class

• Future market analysis right through to 2023

• Analysis of key brands, generics, strategies in-place today and future strategies over the next 15 years

• Analysis of key players in the pain market, current and future licensing strategies

This report examines the global pain drug market critically through a comprehensive review of available information. Sources used include internal databases, industrial databases, commercial news, company reports, published reports and economic research. Visiongain applies in-house financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The Global Pain Market, 2008-2023 concentrates on the following essential aspects of the market:

• Forecast for the worldwide pain pharmaceutical market from 2008 to 2023

• Forecasts for the principal submarkets from 2008 to 2023

• Commercial prospects for the market-leading drugs, with sales forecasts from 2008 to 2023

• Drivers and restraints in the pain market

• Opportunities and threats in the pain market

• Future therapies that will drive growth in this market

• Pipeline developments with significant commercial potential

• Currently marketed drugs with blockbuster potential

• Discussion of unmet therapeutic needs and relative advantages of products.

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for pain drugs from 2008 to 2023

• To discover predicted revenues, growth rates and other key metrics for leading pain treatments from 2008 to 2023

• To discover “hot” pipeline developments and up-and-coming products

• To determine the forces that influence the market for pain drugs:

• Competitive characteristics of the market

• Drivers

• Restraints

• Strengths, weaknesses, opportunities and threats in that market

• To find out where the market is heading - both technologically and commercially – from 2008 onwards.

* Publication date: 13/11/2008

* Number of Pages: 102
Table of Contents

License

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions